Little Rock News Today | 2 Min News | The Daily News Today!
The FDA expedites reviews for three psychedelic drugs, aiming to combat mental health issues like depression and PTSD. Two companies received priority review vouchers for psilocybin and depression, while another got one for methylone and PTSD. The FDA also approved early tests for a safer ibogaine derivative for alcohol use disorder. This push for psychedelics gains traction among Trump supporters, veterans, and health advocates, despite federal Schedule One classification.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/2da3866ae176f058